The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
研究了药品上市后推广活动与不良反应报告之间的关系，通过建模分析监管机构与制药企业的互动，发现推广和广告增加可能导致某些条件下不良反应报告增多。
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug reactions (ADRs) by modeling the interaction between a regulator (the FDA) and a pharmaceutical firm. Promotion-driven market expansions enhance profitability yet may involve the risk of inappropriate drug prescriptions, leading to regulatory actions against the firm. We empirically test the relationship between drug promotion and reporting of ADRs using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and ADRs. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of ADRs for certain conditions.